Jack Higgins - 15 Aug 2024 Form 4 Insider Report for Immunome Inc. (IMNM)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
19 Aug 2024, 21:05:08 UTC
Prior SEC filing
13 Aug 2024
Next SEC filing
28 Mar 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Sandra Stoneman, Attorney-in-Fact

Key filing fact

Jack Higgins filed Form 4 for Immunome Inc. (IMNM) on 19 Aug 2024.

Key facts

  • This page summarizes Jack Higgins's Form 4 filing for Immunome Inc. (IMNM).
  • 4 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 19 Aug 2024, 21:05.

Change

  • Previous filing in this sequence was filed on 13 Aug 2024.
  • Current net transaction value: -$22,714.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMNM transaction

Common Stock

Options Exercise

Transaction value
$26,357
Shares
+19,524
Change %
Price
$1.35
Shares after
19,524
Date
15 Aug 2024
Ownership
Direct
IMNM transaction

Common Stock

Sale

Transaction value
$49,072
Shares
-3,524
Change %
-18%
Price
$13.92
Shares after
16,000
Date
15 Aug 2024
Ownership
Direct
Footnotes
F1, F2
IMNM transaction

Common Stock

Gift

Transaction value
$0
Shares
-2,471
Change %
-15%
Price
$0.000000
Shares after
13,529
Date
19 Aug 2024
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMNM transaction Derivative

Stock option (right to buy)

Options Exercise

Transaction value
$0
Shares
-19,524
Change %
-9.8%
Price
$0.000000
Shares after
179,040
Date
15 Aug 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
19,524
Exercise price
$1.35
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares were sold pursuant to sell to cover transactions.

Footnote F2

The weighted average sale price for the transaction report was $13.925, and the range of prices were between $13.800 and $14.020. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

Footnote F3

25% of the shares vested on May 1, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .